Loading clinical trials...
Loading clinical trials...
Screening, diagnosis and treatment of HCV in PWID, should be part of a harm reduction strategy. Treatment of HCV infected PWID should be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population. More frequent diagnosis, new methods that prevent loss of tracking, and access to antiviral treatment are all strategies that must be implemented jointly if the prevalence of HCV infection in our setting is to be reduced.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Start Date
January 15, 2017
Primary Completion Date
December 31, 2018
Completion Date
May 10, 2019
Last Updated
September 13, 2019
529
ACTUAL participants
Screening for HCV in PWID and Linkage-To-Care
OTHER
Lead Sponsor
Hospital Universitario Infanta Leonor
Collaborators
NCT06372899
NCT06843213
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions